PC-006 · growth-hormone · cjc-1295
CJC-1295
CJC-1295 DAC
Also: Modified GRF 1-29 · Drug Affinity Complex
§ Overview
A synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version binds to albumin, extending its half-life significantly. Often stacked with Ipamorelin for synergistic effects.
§ Mechanism
Binds to GHRH receptors on the anterior pituitary somatotroph cells, stimulating growth hormone synthesis and secretion. The DAC modification allows covalent binding to serum albumin, extending half-life from minutes to days.
§ Common Uses
- → Growth hormone optimization
- → Fat loss
- → Muscle growth
- → Anti-aging
- → Sleep quality improvement
§ Reported Side Effects
- · Water retention
- · Tingling/numbness
- · Flushing
- · Headache
- · Increased hunger
§ Research, Experiences & Trends
Mechanism of Action
Binds to GHRH receptors on the anterior pituitary somatotroph cells, stimulating growth hormone synthesis and secretion. The DAC modification allows covalent binding to serum albumin, extending half-life from minutes to days.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Water retention
- • Tingling/numbness
- • Flushing
- • Headache
- • Increased hunger